DSM renews €500 million credit facility
Royal DSM, the global Life Sciences and Materials Sciences company, today announces that it has entered into a committed credit facility of €500 million with certain credit relationship banks. This facility replaces a previous facility of the same amount which was scheduled to expire in October 2012.
The unsecured credit facility of €500 million is for a minumum term of 5 years and a maximum term of 7 years. In addition to this credit facility, DSM has a committed credit facility of €400 million (maturing in April 2013) as well as a commercial-paper program amounting to €1,500 million. DSM will use the commercial-paper program to a total of not more than €900 million. The agreements for the committed credit facilities neither have financial convenants nor material adverse changes clauses. The credit facilities and commercial-paper program are fully undrawn.
DSM is rated A3 by Moody's and A by Standard & Poor's, both with a stable outlook.
DSM - Bright Science. Brighter Living.(TM)
Royal DSM N.V. is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of about €9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com
For more information:
DSM Corporate CommunicationsHerman Bettentel. +31 (0) 45 5782017 fax +31 (0) 45 5740680 e-mail media.relations@dsm.com |
DSM Investor Relations Hans Vossen tel. +31 (0) 45 5782864 fax +31 (0) 10 4590275 e-mail investor.relations@dsm.com |
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: DSM N.V. via Thomson Reuters ONE
-
Most popular related searches
Related news
-
The Chinese University of Hong Kong and Aurora Medical Technology Hong Kong to collaborate on breast cancer research program
Aurora Medical Technology Hong Kong (Aurora-HK) and The Chinese University of Hong Kong (CUHK) are pleased to announce the completion of a landmark collaboration agreement leveraging the shared interests and diverse expertise of the two entities.Led by Winnie chiu-wing Chu MD, Professor of radiology at CUHK and Abraham Morse MD, Medical Director of Aurora, the joint project will investigate the potential advantages and challenges of using breast-dedicated MRI for first-line breast cancer screening in Chinese...
-
Riskonnect Addresses Financial Services and Healthcare Market Risks with New Platform Capabilities
Riskonnect, the leader in integrated risk management (iRM) solutions, today announces the latest version of its platform Riskonnect 2021.1. Among other enhancements, the release delivers two new major capabilities within the governance, risk, and compliance (GRC) suite specifically designed to help UK financial services organizations build resilience and improve decision making. The release also includes several new features within Riskonnect’s Healthcare Patient Safety and Risk Management Solution that...
-
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk adult patients with mild to moderate COVID-19. Results showed that investigational bamlanivimab (LY-CoV555) 700 mg co-administered with VIR-7831 (also known as GSK4182136) 500 mg demonstrated a 70 percent (p5.27; cycle threshold value < 27.5) at day 7 compared to placebo, meeting the primary endpoint. In addition,...
-
Lakhmir Chawla, MD, of Silver Creek Pharmaceuticals Joins ExThera Medical Board of Directors
Professor Lakhmir Chawla, MD, has joined the board of directors of ExThera Medical Corporation, a privately held medical technology company whose Seraph 100 Microbind Affinity Blood Filter is authorized in the United States to treat critically ill COVID-19 patients. Dr. Chawla also serves as the Chair of the Scientific Advisory Board at the company Dr. Chawla is an internationally renowned expert in the field of acute kidney injury (AKI), vasopressors, and septic shock. He remains an active investigator in the...
-
Intersect ENT to Participate at the Oppenheimer 31st Annual Healthcare Conference
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference. The fireside chat will take place on Wednesday, March 17, 2021 at 2:30 p.m. ET / 11:30 a.m. PT. To access the webcast, go to the...
Customer comments
No comments were found for DSM renews €500 million credit facility. Be the first to comment!